Study on the clinical efficacy of baicalin combined with metformin in patients with type 2 diabetes

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100051281

Enrollment

Unknown

Registered

2021-09-17

Start date

2021-09-20

Completion date

Unknown

Last updated

2022-08-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes

Interventions

control group:metformin

experimental group:baicalin combined with metfomin

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18 to 65 years; 2. Comply with the diagnostic criteria of the "Guidelines for the Prevention and Treatment of Type 2 Diabetes in China" (2017 edition) and WHO diagnostic criteria (1999 edition); 3. Before entering the group, simply take metformin as a hypoglycemic drug; after a stable dose of metformin single drug (>= 1500mg/day or the maximum tolerated dose, but the maximum tolerated dose should not be less than 1000mg/day) treatment for at least 8 weeks; 4. 7.5% <= HbA1c <=11%; 5. Did not use probiotics or antibiotics within 4 weeks before enrollment; 8. Have not participated in other clinical trials in the past three months; 6. Agree to not participate in any clinical research of any other project in this trial research; agree to participate in this trial and sign a written informed consent form; 7. The patient can provide detailed contact information and is willing to cooperate with the follow-up.

Exclusion criteria

Exclusion criteria: 1. Combined with serious primary diseases such as heart, liver, brain, kidney and hematopoietic system, critically ill, malignant tumors; 2. Patients with acute metabolic disorders such as diabetic ketoacidosis and co-infection in the past month; 3. Severe mental disorders, hysteria; 4. Pregnant or lactating women and those who may be allergic to this drug; 5. Contraindications to metformin hydrochloride tablets. 6. With serious diabetic complications, such as diabetic nephropathy, diabetic retinopathy, diabetic foot, etc..

Design outcomes

Primary

Measure	Time frame
Hemoglobin A1C;Fasting blood glucose;Oral glucose tolerance test;	—

Secondary

Measure	Time frame
blood biochemistry;	—

Countries

China

Contacts

Public ContactYan Dan

Beijing Friendship Hospital, Capital Medical University

yd277@126.com+86 13488678873

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 5, 2026